Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing-remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after treatment initiation, he developed slowly progressing neurological deficits including gait impairment, paraesthesia of the lower limbs, strangury and visual impairment, which led to the discontinuation of adalimumab therapy. Magnetic resonance imaging of the brain and the spinal cord revealed multiple inflammatory lesions and cerebrospinal fluid examination showed slight pleocytosis and positive oligoclonal bands. Thus, PPMS was diagnosed according to the 2017 revision of the McDonald criteria. As PPMS often causes only subtle symptoms in the beginning and early treatment discontinuation of anti-TNF-α therapy seems essential to improve the patient's outcome, we think that it is important to increase the awareness of slowly progressing neurological deficits as a potential adverse event of anti-TNF-α therapy among all clinicians involved in the initiation and monitoring of these drugs. In addition, the occurrence of both RRMS and progressive MS upon anti-TNF-α therapy might suggest a shared TNF-α-mediated pathophysiological mechanism in the evolution of all MS subtypes.
Keywords: adalimumab; anti-TNF-alpha therapy; primary progressive multiple sclerosis.
© The Author(s), 2020.
Conflict of interest statement
Conflict of interest statement: Sinah Engel, Aneka Mueller, Felix Luessi, Frauke Zipp and Stefan Bittner report no conflicts of interest associated with the publication of this manuscript. Rudolf E. Schopf has received honoraria/travel reimbursements from AbbVie, which were not associated with the submitted work.
[Neurological adverse events under anti-TNF alpha therapy].Rev Neurol (Paris). 2012 Jan;168(1):33-9. doi: 10.1016/j.neurol.2011.06.005. Epub 2011 Nov 17. Rev Neurol (Paris). 2012. PMID: 22098827 French.
Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.Arthritis Res Ther. 2014 Jun 17;16(3):R125. doi: 10.1186/ar4582. Arthritis Res Ther. 2014. PMID: 24938855 Free PMC article.
Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.Mult Scler. 2009 Dec;15(12):1459-65. doi: 10.1177/1352458509348422. Epub 2009 Dec 7. Mult Scler. 2009. PMID: 19995843 Clinical Trial.
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Clin Rheumatol. 2013 Feb;32(2):271-5. doi: 10.1007/s10067-012-2113-2. Epub 2012 Nov 14. Clin Rheumatol. 2013. PMID: 23149905 Review.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173. - PubMed
- Solomon AJ, Spain RI, Kruer MC, et al. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011; 17: 1472–1487. - PubMed
- Bosch X, Saiz A, Ramos-Casals M, et al. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011; 7: 165–172. - PubMed
- Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011; 41: 524–533. - PubMed